Table 1. Patients' characteristics (absolute and percentage value) according to single cohort.
| Cohort A | Cohort B | Cohort C | |
|---|---|---|---|
|
Age (years) | |||
| Median | 79.4 | 75.0 | 78.51 |
| Range |
67.5–93.8 |
67.2–95.4 |
65.0–88.4 |
| No. of patients |
40 |
40 |
40 |
|
PgR status | |||
| PgR+ | 35 (87.5) | 32 (80.0) | 32 (80.0) |
| PgR− |
5 (12.5) |
8 (20.0) |
8 (20.0) |
|
HER-2 status | |||
| HER2+ | 2 (5.0) | 5 (12.5) | 1 (2.5) |
| HER2− |
38 (95.0) |
35 (87.5) |
39 (97.5) |
|
Ki-67 expression | |||
| Median | 13 | 13.5 | 15 |
| Range | 5–35 | 2–90 | 2–32 |
| <14% | 21 (52.5) | 20 (50.0) | 17 (42.5) |
| ⩾14% |
19 (47.5) |
20 (50.0) |
23 (57.5) |
|
Grade | |||
| I | 2 (5.0) | 0 | 0 |
| II | 24 (60.0) | 27 (67.5) | 23 (57.5) |
| III | 13 (32.5) | 13 (32.5) | 17 (42.5) |
| NA |
1 (2.5) |
0 |
0 |
|
Histotype | |||
| DIC | 24 (60.0) | 32 (80.0) | 29 (72.5) |
| LIC | 8 (20.0) | 5 (12.5) | 5 (12.5) |
| Mixed DIC-LIC | 3 (7.5) | 2 (5.0) | 3 (7.5) |
| Other |
5 (12.5) |
1 (2.5) |
3 (7.5) |
|
Clinical stage | |||
| T2 | 35 (87.5) | 30 (75.0) | 28 (70.0) |
| T3 | 0 | 4 (10.0) | 3 (7.5) |
| T4 | 4 (10.0) | 6 (15.0) | 8 (20.0) |
| NA | 1 (2.5) | 0 | 1 (2.5) |
| N0 | 31 (77.5) | 32 (80.0) | 33 (82.5) |
| N1 | 5 (15.0) | 8 (20.0) | 4 (10.0) |
| NA | 3 (7.5) | 0 | 3 (7.5) |
Abbreviations: DIC=ductal infiltrating carcinoma; LIC=lobular infiltrating carcinoma; NA=not available; PgR=progesterone receptor.
The three cohorts of patients were comparable in terms of age at the start of neoadjuvant treatment, basal clinical dimensions, tumoral grade, histotype, PgR and HER2 status, and Ki-67 value.